相关实验视频

Updated: Feb 28, 2026

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Published on: August 4, 2016

对新型希夫基的全面调查:合成,抗癌效果,基因表达概况和计算分析

Tugba Agbektas¹, Özhan Pazarcı², Ayca Tas³

¹Department of Food Processing Technologies Services, Yıldızeli Vocational School, Sivas Cumhuriyet University, Sivas 13001, Türkiye.

Pharmaceuticals (Basel, Switzerland)

|February 27, 2026

概括

一种新型化合物B-134-0通过诱导DNA损伤和亡,对骨髓瘤细胞产生显著的抗癌作用. 这种阿佐梅丁衍生物显示出强大的细胞毒性,并调节关键基因表达,突出其治疗潜力.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

骨髓瘤是一种主要的骨癌,有效治疗方法有限.
迫切需要针对癌症特定途径的新型治疗剂.

研究的目的:

为了评估一种新的以亚甲为基础的化合物 (B-134-0) 对骨髓瘤 (SAOS-2) 细胞的抗癌潜力.
为了研究该化合物对亡和DNA损伤反应 (DDR) 基因表达的影响.

主要方法:

B-134-0.的合成和表征
使用MTT测定进行体外细胞毒性评估.
定量PCR (qPCR) 用于分析TP53,RAD51,BRCA2,CASP2,MYC,MDM2,CDKN1A,ERCC1,ATR和PRKDC的基因表达. 这种基因表达的基因表达是指基因表达的基因表达的基因表达的基因表达.
用于结构和相互作用研究的分子对接和DFT分析.

主要成果:

B-134-0对SAOS-2细胞表现出显著的时间依赖性细胞毒性 (IC50值随着长时间暴露而降低).
该化合物调节细胞周期和DNA修复基因的表达,降低TP53,RAD51,CASP2,MYC和MDM2的调节,同时提高CDKN1A和BRCA2的调节.
分子对接证实与BRCA2和CDKN1A具有强烈的结合亲和力,支持观察到的基因表达变化.

结论:

B-134-0 具有强大的抗癌活性,对抗骨髓瘤细胞.
该化合物有效调节DNA损伤反应和亡途径.
由于其有效性和分子稳定性,B-134-0显示为骨髓瘤治疗的潜在治疗候选人.

关键词:

在 DFT 方面,它是最重要的.这就是SAOS-2.抗癌药物是一种抗癌药物.基因表达的基因表达方式磁力学分析分析分析分子对接的分子对接.

更多相关视频

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...